CD8A and melanoma: To investigate tumor-killing capability of STZ-diabetic CD8+ T cells in vivo, B16-gp33 melanoma cells were subcutaneously inoculated, followed by adoptive transfer of the tumor-specific P14 CD8+ effector cells intravenously (Figure 3A).